Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check3 days agoChange DetectedRegional names Královéhradecký kraj and Olomoucký kraj were updated to Hradec Králové Region and Olomouc Region, respectively, with the corresponding addresses adjusted. The revision tag was updated to v3.5.2.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedAdded Padova, Italy, 35128 and removed Padua, Italy, 35128 from the locations list.SummaryDifference0.0%

- Check24 days agoChange DetectedNapoli, Italy, 80131 was replaced with Naples, Italy, 80131 in the locations section.SummaryDifference0.0%

- Check32 days agoChange DetectedRevision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check68 days agoChange DetectedRevision: v3.4.2 was added to replace Revision: v3.4.1 on the page. This appears to be a minor site version update not affecting study details.SummaryDifference0.0%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.